SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ACV Auctions Inc. (ACVA)

Brodsky & Smith is investigating ACV Auctions' board over its proposed sale to Copart for $10.50 per share in cash, implying approximately $1.9 billion of equity value. The law firm alleges the board may have breached fiduciary duties by failing to run a fair process and potentially accepting inadequate consideration for ACV shareholders. The announcement creates transaction-related legal risk, though it does not itself establish wrongdoing or indicate a change to the deal terms.

Analysis

This is not a fundamental litigation signal; plaintiff-firm announcements are a routine post-deal event and rarely alter closing economics absent a credible competing bidder, a disclosed process defect, or a material regulatory issue. ACVA should trade primarily on the discount to $10.50: a persistently wide spread would indicate market concern about antitrust review or deal timing, not this investigation. For CPRT, the relevant issue is whether it can retain ACV's dealer relationships and improve auction liquidity without triggering adverse dealer or OEM channel responses.

The more consequential second-order effect is competitive consolidation in digital wholesale auto auctions. A combined CPRT/ACVA could pressure KAR's OPENLANE (KAR) and private-market platforms by bundling inspection, transportation, title and remarketing services; however, overlapping customers may create retention risk if ACV's dealer-first pricing is repriced toward CPRT economics. Synergies are likely back-end loaded over 12-24 months because marketplace liquidity and local inspection operations cannot be rationalized aggressively without impairing conversion and seller supply.

Near term, ACVA's upside is capped at cash consideration unless a superior proposal appears, while its downside is governed by stand-alone execution if the merger breaks. CPRT's valuation impact should be modest initially, but the stock could rerate lower if management signals materially higher integration spend, customer attrition, or a protracted review that delays synergy realization. The actionable monitor is the ACVA merger-arbitrage spread versus the expected close date; legal headlines alone should not change positioning.

Key Decisions for Investors

• Do not trade ACVA solely on the law-firm announcement. Consider merger-arbitrage long ACVA only if the annualized gross spread compensates for a break scenario below $10.50 and diligence confirms customary financing, shareholder and regulatory conditions; size as event risk, not as a litigation catalyst.
• Maintain/watch a relative-value long CPRT / short KAR position over 6-18 months only after reviewing transaction terms and antitrust exposure. The thesis is CPRT monetizing ACV's dealer network and data footprint faster than KAR can defend marketplace liquidity; invalidate on elevated ACV dealer churn or evidence that CPRT must preserve ACV pricing and cost structure.
• For existing CPRT longs, use the next earnings call as the key 1-3 month catalyst: reduce if management raises integration costs, delays closing, or declines to quantify revenue-retention assumptions. A favorable close timeline with stable core margins supports holding through the 12-24 month synergy window.
• Set an alert on ACVA trading materially below deal value after definitive merger documentation is available. A widening spread accompanied by an HSR/competition request, rather than litigation press releases, would create the only potentially attractive incremental return opportunity.